

Biosimilars Global Market To Grow At Rate Of 22% Through 2026

*The Business Research Company's
Biosimilars Global Market Report 2022–
Market Size, Trends, And Global Forecast
2022-2026*

LONDON, GREATER LONDON, UK,
February 11, 2022 /EINPresswire.com/
-- According to 'Biosimilars Global
Market Report 2022 – Market Size,
Trends, And Global Forecast 2022-2026'

published by The Business Research Company, the biosimilars market size is expected to grow from \$15.67 billion in 2021 to \$19.10 billion in 2022 at a compound annual growth rate (CAGR) of 21.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar market is expected to reach \$42.30 billion in 2026 at a CAGR of 22%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.

Want to learn more on the biosimilars market growth? Request for a Sample now:
<https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp>

The global biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired.

[Global Biosimilars Market Trends](#)

Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers.

[Global Biosimilars Market Segments](#)

The global biosimilars market is segmented:



The Business
Research Company

Biosimilars Global Market Report 2022 – Market Size,
Trends, And Global Forecast 2022-2026

By Product: Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins
By Type: Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Others
By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others
By Geography: The global biosimilar market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America accounts for the largest share.

Read more on the global biosimilars market report at:

<https://www.thebusinessresearchcompany.com/report/biosimilars-global-market-report>

Biosimilars Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides market overviews, analyzes and forecasts market size and growth for the global biosimilars market, share, segments and geographies, trends, players, leading competitor revenues, profiles and market shares. The biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors' approaches.

TBRC's Biosimilars Global Market Report 2022 includes information on the following:

Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan plc, BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan Plc., Hospira International., Actavis International., Johnson & Johnson and Roche.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company: Biosimilar Lymphocyte Modulator Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-lymphocyte-modulator-global-market-report>

Biosimilar Hormones Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-hormones-global-market-report>

Biosimilar Interleukins Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/biosimilar-interleukins-global-market-report>

About The Business Research Company

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/562839541>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.